The secret life of anti-cancer drugs
But what happens to these drugs? When do they become accessible to cancer patients — if at all? In a new review published in ecancermedicalscience, researchers trace the journey anti-cancer drugs take between discovery and clinical practice. “Bringing a new medication to clinical practice is a lengthy process and involves many stakeholders with a very diverse background, ranging from researchers, regulatory agencies, payers, physicians and patients,” says Dr Felipe Ades of the Jules Bordet Institute, lead author of the review…